NEW YORK – SpectronRx on Wednesday said it will manufacture radiopharmaceutical products for Radioisotope Life Sciences (RLS) and other partners, while RLS will distribute the products, under a new partnership agreement.
South Bend, Indiana-based SpectronRx will also provide quality control testing and regulatory compliance services. RLS will distribute the products, which are typically limited in supply and have short half-lives, as individual doses to providers as needed. RLS owns and operates 31 radiopharmacies in 18 states.
The partnership also includes opportunities for the companies to collaborate on research and development projects and advance nuclear medicine treatments.
"Our collaboration will not only help RLS expand our extensive, accredited network of radiopharmacies into oncology, it will also improve access to novel, lifesaving radioisotope-based medicines, which are vital in delivering precision medicine solutions for patients everywhere," RLS CEO Stephen Belcher said in a statement.